Chengdu Huasun Group Inc., Ltd. (SZSE: 000790) announced yesterday that its biological tech subsidiary has been supported by China in doing an anticancer research.
The research is concerned with the utilization of Iodine [131I] Metuximab Injection to reduce recurrence of liver cancer after resection or ablation. The subsidiary will be supported by the special item of "developing crucial new drug" under China's "12th Five-Year Plan". Meanwhile, the research has been examined by the the medical ethics committee of Zhongshan Hospital Fudan University
Source:
http://www.sinocast.com/readbeatarticle.do?id=94857
